Chemotherapy for pancreatic cancer

Last medical review:

Chemotherapy uses drugs to destroy cancer cells. These drugs target rapidly dividing cells throughout the whole body. This means that chemotherapy kills cancer cells but it can also damage healthy cells.

With most types of chemotherapy, the drugs travel through the blood to reach and destroy cancer cells all over the body, including cells that may have broken away from the primary tumour. This is described as systemic therapy.

Most people with pancreatic cancer have chemotherapy at some point during their treatment. If you have chemotherapy, your healthcare team will use what they know about the cancer and about your health to plan the drugs, doses and schedules.

Chemotherapy may be the only treatment you have, or it may be used along with other cancer treatments. You may have chemotherapy to:

  • treat unresectable pancreatic cancer
  • shrink a borderline resectable tumour before surgery to try to make it resectable (called neoadjuvant chemotherapy)
  • destroy cancer cells left behind after surgery and reduce the risk that the cancer will come back (recur) (called adjuvant chemotherapy)
  • kill cancer cells that may have broken off and spread (called micrometastasis) before surgery for resectable cancer (called neoadjuvant therapy)
  • relieve pain or control the symptoms of advanced or metastatic pancreatic cancer (called palliative chemotherapy)

Chemotherapy drugs used for pancreatic cancer

Pancreatic cancer is usually treated with a combination of chemotherapy drugs. The most common chemotherapy drug combinations used are:

  • FOLFIRINOX – irinotecan, oxaliplatin, fluorouracil (also called 5-fluorouracil or 5-FU) and leucovorin
  • gemcitabine and nab-paclitaxel
  • gemcitabine and capecitabine
  • fluorouracil and leucovorin
  • gemcitabine and cisplatin
  • oxaliplatin, fluorouracil and leucovorin
  • nanoliposomal irinotecan, fluorouracil and leucovorin
  • irinotecan, fluorouracil and leucovorin

The most common chemotherapy drugs used on their own for pancreatic cancer include:

  • gemcitabine
  • capecitabine
  • fluorouracil
  • irinotecan
  • nab-paclitaxel
  • oxaliplatin
  • cisplatin

All of these chemotherapy drugs and drug combinations are given through a needle into a vein (intravenously) except for capecitabine, which is given as a pill by mouth (orally). How long you have chemotherapy for depends on the drugs and doses given, if you have any other treatments and the cancer's response to treatment.

Nanoliposomal irinotecan may not be available at all treatment centres or covered by all provincial and territorial health plans. Your healthcare team will talk to you about your options if they think you may benefit from this drug.

Chemoradiation

Chemotherapy and radiation therapy may be given during the same time period to treat pancreatic cancer. This is called chemoradiation. Some chemotherapy drugs can help make radiation work better by making cancer cells more sensitive to radiation. Combining chemotherapy and radiation therapy can be more effective than either treatment on its own.

Chemotherapy drugs used in chemoradiation for pancreatic cancer include:

  • gemcitabine
  • fluorouracil
  • capecitabine

Chemoradiation is often given after you have had chemotherapy for pancreatic cancer. You may also have more chemotherapy treatment after chemoradiation.

Side effects

Side effects of chemotherapy will depend mainly on the drug, the dose, how it's given, and your overall health. Tell your healthcare team if you have side effects that you think are from chemotherapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.

Common side effects of chemotherapy drugs for pancreatic cancer include:

Find out more about chemotherapy

Find out more about chemotherapy and side effects of chemotherapy. To make the decisions that are right for you, ask your healthcare team questions about chemotherapy.

Details on specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.

Expert review and references

  • George Zogopoulos, MD, PhD, FRCSC, FACS
  • Steven Gallinger, MD, MSc, FRCSC
  • American Cancer Society. Chemotherapy for Pancreatic Cancer. 2024. https://www.cancer.org/.
  • American Cancer Society. Treating Pancreatic Cancer, Based on Extent of the Cancer. 2024. https://www.cancer.org/.
  • Arnason T, Colwell B, Costa A, et al.. Guidelines for Adenocarcinoma of the Pancreas. Halifax, NS: Cancer Care Nova Scotia; 2020. https://www.nshealth.ca/cancer-care/.
  • Cancer Care Ontario. Regime Monograph: CAPE. 2018. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regimen Monograph: CAPEGEMC. 2023. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: CAV. 2019. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: CISPIRIN. 2023. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: CRBETOP. 2023. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: FOLFNALIRI. 2023. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: FU(CIV-RT). 2023. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: FULCVR. 2023. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: GEMC. 2021. https://www.cancercareontario.ca/en.
  • Cancer Care Ontario. Regime Monograph: GEMCNPAC(W). 2024. https://www.cancercareontario.ca/en.
  • Cancer Research UK. Chemotherapy for Pancreatic Cancer. 2023. https://www.cancerresearchuk.org/.
  • Guideline Resource Unit (GURU). Adenocarcinoma of the Pancreas. Edmonton: Alberta Health Services; 2021: Clinical Practice Guideline GI-006 Version: 10. https://www.albertahealthservices.ca/info/cancerguidelines.aspx.
  • Hosni A, Elamir A, Knox J, McNamara M. Princess Margaret Cancer Center Clinical Practice Guidelines: Gastrointestinal, Pancreatic. University Health Network; 2019.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 2.2024. 2024.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Adjuvant Chemotherapy for Pancreatic Adenocarcinoma Using Gemcitabine. Vancouver, BC: 2022. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Capecitabine and Gemcitabine. Vancouver, BC: 2023. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin. Vancouver, BC: 2023. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel NAB (ABRAXANE) and Gemcitabine. Vancouver, BC: 2024. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Platinum. Vancouver, BC: 2024. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Palliative Chemotherapy for Pancreatic Adenocarcinoma, Gallbladder Cancer, and Cholangiocarcinoma Using Gemcitabine. Vancouver, BC: 2021. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin. Vancouver, BC: 2023. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using Oxaliplatin, Fluorouracil, and Leucovorin. Vancouver, BC: 2023. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Second Line Treatment for Metastatic Pancreatic Cancer using Irinotecan, Fluorouracil and Leucovorin. Vancouver, BC: 2023. https://www.bccancer.bc.ca/.
  • Provincial Health Services Authority. BC Cancer Protocol Summary: Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma using Capecitabine. Vancouver, BC: 2023. https://www.bccancer.bc.ca/.
  • Siddiqui J. Treatment of borderline resectable and locally advanced pancreatic cancer – Summary. Eastern Health Cancer Care. Clinical Practice Guidelines – Gastrointestinal Disease Site. St. John's, NL: Newfoundland Health Services; 2014. https://cancercare.easternhealth.ca/.
  • Tremblay A, Cook N, Gallinger S, Dhani N. University Health Network Guidelines for Management of Resectable, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC). University Health Network; 2015.
  • Winter JM, Brody JR, Abrams RA, Posey JA, Yeo CJ. Cancer of the pancreas. DeVita VT Jr, Lawrence TS, Rosenberg S. eds. DeVita Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, PA: Wolters Kluwer; 2023: Kindle version, chapter 55, https://read.amazon.ca/?asin=B0BG3DPT4Q&language=en-CA.

Your trusted source for accurate cancer information

With just $5 from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

If everyone reading this gave just $5, we could achieve our goal this month to fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society